# High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV

> **NCT00381953** · PHASE3 · COMPLETED · sponsor: **Foundation for Liver Research** · enrollment: 33 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Peginterferon alfa-2a
- **DRUG:** Interferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00381953
- **Lead sponsor:** Foundation for Liver Research
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2006-04
- **Final completion:** 2006-07
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2021-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00381953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00381953, "High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT00381953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*